Edwards’ High Wire Act In TAVI: An Interview With Mike Mussallem
Given the competing interests and different challenges – balancing internal R&D with external M&A, managing rival customer groups, and tackling a tough regulatory path to name just three – Edwards Lifesciences’ success in TAVI may be even more impressive than it looks. IN VIVO interviews CEO Mike Mussallem about how Edwards developed TAVI and the obstacles and challenges the company faced along the way.
You may also be interested in...
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.